Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Short-term Investments (2018 - 2025)

Historic Short-term Investments for China SXT Pharmaceuticals (SXTC) over the last 6 years, with Q3 2025 value amounting to $31001.0.

  • China SXT Pharmaceuticals' Short-term Investments changed N/A to $31001.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $31001.0, marking a year-over-year change of. This contributed to the annual value of $30413.0 for FY2025, which is 34450.45% up from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Short-term Investments stood at $31001.0 for Q3 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Short-term Investments ranged from a high of $45297.0 in Q1 2022 and a low of $6842.0 during Q1 2024
  • Its 4-year average for Short-term Investments is $27900.0, with a median of $30413.0 in 2025.
  • Its Short-term Investments has fluctuated over the past 5 years, first surged by 7457.51% in 2022, then surged by 34450.45% in 2025.
  • Quarter analysis of 4 years shows China SXT Pharmaceuticals' Short-term Investments stood at $25947.0 in 2021, then skyrocketed by 74.58% to $45297.0 in 2022, then plummeted by 84.9% to $6842.0 in 2024, then surged by 353.1% to $31001.0 in 2025.
  • Its Short-term Investments stands at $31001.0 for Q3 2025, versus $30413.0 for Q1 2025 and $6842.0 for Q1 2024.